EC Number |
Application |
Reference |
---|
2.3.1.43 | drug development |
a therapeutic that increases enzyme LCAT activity may promote reverse cholesterol transport and prove beneficial for the treatment of dyslipidaemia and atherosclerosis |
737191 |
2.3.1.43 | drug development |
LCAT is a potential drug target for reducing atherosclerosis |
705507 |
2.3.1.43 | drug development |
rational development of therapeutics to treat enzyme LCAT deficiency, atherosclerosis and acute coronary syndrome |
736865 |
2.3.1.43 | medicine |
a complementary effect between myristic acid and alpha-linolenic acid that exerts a positive impact on the metabolism of plasma HDL by activating LCAT |
688771 |
2.3.1.43 | medicine |
a therapeutic that increases enzyme LCAT activity may promote reverse cholesterol transport and prove beneficial for the treatment of dyslipidaemia and atherosclerosis |
737191 |
2.3.1.43 | medicine |
carotid artery intima media thickness (IMT) is greater and plasma LCAT activity is higher in subjects with metabolic syndromes compared to control. Similar increases in IMT and LCAT are found in MetS subjects without type 2 diabetes mellitus. In addition, plasma LCAT activity is independently and positively related to insulin resistance, plasma triglycerides, non-HDL cholesterol and HDL cholesterol. LCAT activity may be a marker of subclinical atherosclerosis |
687969 |
2.3.1.43 | medicine |
haptoglobin from psoriatic patients exhibits decreased activity in binding haemoglobin and inhibiting LCAT |
688067 |
2.3.1.43 | medicine |
hemoglobine A1c concentration negatively correlates with LCAT activity in type 2 diabetes patients |
686314 |
2.3.1.43 | medicine |
in patients bearing a homozygous -629CC polymorphism of the cholesteryl ester transfer protein promoter a higher LCAT activity is measured |
685374 |
2.3.1.43 | medicine |
it is shown that LCAT activity is lower in pregnancy induced hypertension (PIH) and chronic hypertensive (CH) mothers than in normotensive controls. Similar changes are observed in small for gestational age (SGA) newborns of PHI mothers and in SGA newborns of CH mothers when compared to appropriate for gestational age newborns of control mothers (AGA-NC) |
686547 |